Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine

AIDS

Volumn 13, Issue 7, 1999, Pages 805-810

  Martínez, Esteban ^a   Conget, Ignacio ^a   Lozano, Luisa ^a   Casamitjana, Roser ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Fat redistribution; Metabolism abnormalities; Protease inhibitors

Indexed keywords

CD4 ANTIGEN; CHOLESTEROL; GLUCOSE; INSULIN; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY BUILD; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; METABOLISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; T LYMPHOCYTE;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TRIGLYCERIDES;

EID: 0032903844     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00009     Document Type: Article

References (23)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998, 280:78-86.
2. 2. Tashima K, Satszewski S, Stryker R, et al.: A phase III multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz plus indinavir versus efavirenz plus zidovudirte plus lamivudine versus indinavir plus zidovudine plus lamivudine at 48 weeks (Study DMP 266-006). 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract LB16].
3. 3. Katlama C, Murphy K, Johnson V, et al.: The Atlantic study: a randomised open-label study comparing protease inhibitor-sparing antiretroviral strategics versus a standard protease inhibitors-containing regimen. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 18].
4. 4. Finzi D, Hirmankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
5. 5. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of HIV viremia. Science 1997, 278:1211-1215.
6. 6. Reijers MH, Weverling GJ, Jurriaans S, et al.: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
7. 7. Havlir DV, Marschner IC, Hirsch MS, et al.: Maintenance antiretroviral therapies in HIV-1 infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998, 339:1261-1268.
8. 8. Pialoux G, Raffi F, Brun-Vezinet F, et al.: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998, 339:1269-1276.
9. 9. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
10. 10. Martínez E, Casamitjana R, Conget I, Gatell JM: Protease inhibitor-associated hyperinsulinaemia [letter]. AIDS 1998, 12:2077-2079.
11. 11. Viraben R, Aquilina C: Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-F39.
12. 12. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan J: 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
13. 13. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein Y, Fallon J: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
14. 14. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
15. 15. Kotler DP: Truncal obesity, 'Crix-belly' - Is it what it appears to be ... or something else? Medscape HIV/AIDS 1998, 4(1). (http://hiv.medscape.com/medscape/h...v04.nol/expert0298).
16. 16. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514-1520.
17. 17. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
18. 18. Cleeman JI: Detection and evaluation of dyslipoproteinemia. Endocrinol Metab Clin North America 1998, 27:597-611.
19. 19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998, 21 (suppl 1):S5-S19.
20. 20. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J: A simple measure of insulin resistance. Lancet 1995, 346:120-121.
21. 21. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight among U.S. adults: the national health and nutrition examination surveys, 1960-1991. JAMA 1994, 272:205-211.
22. 22. Molarius A, Seidell JC: Selection of anthropometric indicators for classification of abdominal fatness: a critical review. Int J Obes 1998, 22:719-727.
23. 23 Abate N, Garg A: Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 1995, 34:53-70.